Temporal validation of the Ramathibodi Older Sepsis Score (ROSS) for predicting 28-day mortality of older sepsis patients in the emergency department
Issued Date
2025-12-01
Resource Type
eISSN
1471227X
Scopus ID
2-s2.0-105022233876
Pubmed ID
41254509
Journal Title
BMC Emergency Medicine
Volume
25
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Emergency Medicine Vol.25 No.1 (2025)
Suggested Citation
Sanguanwit P., Nilkosit N., Yuksen C., Vichiensanth P., Termkijwanich P. Temporal validation of the Ramathibodi Older Sepsis Score (ROSS) for predicting 28-day mortality of older sepsis patients in the emergency department. BMC Emergency Medicine Vol.25 No.1 (2025). doi:10.1186/s12873-025-01382-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113254
Title
Temporal validation of the Ramathibodi Older Sepsis Score (ROSS) for predicting 28-day mortality of older sepsis patients in the emergency department
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Sepsis in older patients is associated with a high mortality rate, presenting a considerable clinical challenge. Existing mortality prediction scoring systems have demonstrated limited accuracy in this population. The Ramathibodi Older Sepsis Score (ROSS) was developed to address this limitation. However, temporal validation is necessary to assess its efficacy in predicting 28-day mortality. Objective: This study aimed to validate the Ramathibodi Older Sepsis Score (ROSS) for predicting 28-day mortality in older sepsis patients in the emergency department (ED). Methods: Data for the development cohort were retrospectively collected from August to December 2018, while data for the validation cohort were collected from January to June 2022. Seven prespecified prognostic factors for 28-day mortality were used to develop a predictive a predictive score and assess its performance. Results: A total of 500 older sepsis patients were included in the validation cohort, and 599 patients were included in the development cohort. The predictive ability of the ROSS model in the validation cohort (Area under receiver operating characteristic curve; AuROC: 0.69, 95% CI: 0.61–0.77) decreased compared to the development cohort (AuROC: 0.87, 95% CI: 0.82–0.92); P < 0.01. This performance was compared with other scoring models: SIRS (AuROC: 0.50, 95% CI: 0.42–0.58; P < 0.01), qSOFA (AuROC: 0.70, 95% CI: 0.64–0.77; P = 0.75), NEWS2 (AuROC: 0.68, 95% CI: 0.60–0.76; P = 0.81), and REWS (AuROC: 0.66, 95% CI: 0.57–0.75; P = 0.51). Conclusion: The temporal validation of the ROSS demonstrated moderate performance in predicting 28-day mortality in older sepsis patients, with AuROC values similar to qSOFA and NEWS2. Although ROSS did not outperform existing scores, it offers geriatric-specific insights and highlights the need for further validation.